Klacid I.V.

Clarithromycin, the active ingredient in Klacid I.V., is a macrolide antibiotic presented as an intravenous solution for intravenous use. It treats a range of bacterial infections such as community‑acquired pneumonia, acute bacterial sinusitis, exacerbations of chronic bronchitis, skin and soft‑tissue infections, and otitis media in adult patients.

GNH USA supplies Klacid I.V. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Clarithromycin is a macrolide antibiotic used to treat bacterial infections of the respiratory tract, skin and ear. - Community‑acquired pneumonia: reduces bacterial load and improves clinical outcomes in adult patients. - Acute bacterial sinusitis: eradicates causative organisms and relieves sinus inflammation. - Acute exacerbations of chronic bronchitis: controls bacterial infection contributing to worsening symptoms. - Skin and soft tissue infections: treats susceptible Gram‑positive and some Gram‑negative pathogens. - Otitis media: eliminates bacterial agents causing middle‑ear infection.

Clarithromycin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools, often self‑limiting. - Abdominal pain: discomfort in the stomach area. - Taste disturbance: altered or metallic taste sensation.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - QT prolongation: cardiac rhythm disturbances that may lead to arrhythmia. - Severe allergic reactions: rash, itching, swelling, or anaphylaxis. - Clostridioides difficile colitis: severe diarrhea due to bacterial overgrowth.

When prescribing clarithromycin intravenous solution, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: adjust therapy and monitor renal function. - Hepatic disease: use with caution and observe liver enzymes. - Cardiac risk: avoid in patients with known QT prolongation or electrolyte disturbances. - Drug‑induced photosensitivity: advise patients to limit exposure to strong sunlight. - Pregnancy category B: use only if benefit outweighs potential risk. - Store at below 25°C: keep in original container, protect from moisture and light.

Clarithromycin interacts with several medicines through enzyme inhibition and other pathways.

Major Interactions (Avoid): - Statins (simvastatin, lovastatin): risk of myopathy and rhabdomyolysis. - Antiarrhythmics (amiodarone, quinidine): increased QT prolongation. - Ergot derivatives (ergotamine): potential ergotism.

Moderate Interactions (Monitor Closely): - Warfarin: enhanced anticoagulant effect, monitor INR. - Theophylline: elevated levels may cause toxicity.